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Prematuredelivery,asignificantcauseofchildmortalityandmorbidityworldwide,isparticularlyprevalentinthedevelopingworld.
As HIV is highly prevalent in much of sub-Saharan Africa, it is important to determine risk factors for prematurity among HIV-
positive pregnancies. The aims of this study were to identify risk factors of preterm (<37 weeks) and very preterm (<34 weeks)
birth among a cohort of 927 HIV positive women living in Dar es Salaam, Tanzania, who enrolled in the Tanzania Vitamin and
HIV Infection Trial between 1995 and 1997. Multivariable relative risk regression models were used to determine the association of
potential maternal risk factors with premature and very premature delivery. High rates of preterm (24%) and very preterm birth
(9%)werefound.Riskfactors(adjustedRR(95%CI))forpretermbirthweremother<20years(1.46(1.10,1.95)),maternalilliteracy
(1.54 (1.10, 2.16)), malaria (1.42 (1.11, 1.81)), Entamoeba coli (1.49 (1.04, 2.15)), no or low pregnancy weight gain, and HIV disease
stage ≥2 (1.41 (1.12, 1.50)). Interventions to reduce pregnancies in women under 20, prevent and treat malaria, reduce Entamoeba
coli infection, and promote weight gain in pregnant women may have a protective effect on prematurity.
1. Introduction
Preterm delivery is recognized as a significant cause of child
mortality and morbidity worldwide. Preterm birth is the
leading cause of neonatal mortality [1]. It is estimated that
preterm birth is the direct cause of 29% of deaths in children
under 28 days and 11% of deaths in children under 5 years
[1–3].
Prematurity disproportionately affects newborns in
resource-constrained countries, where it is both more
common and more often leads to adverse health outcomes.
A systematic review from 2010 reports that 7.5% and 11.9%
o fb i r t h si nd e v e l o p e dc o u n t r i e sa n di nA f r i c a ,r e s p e c t i v e l y ,
were preterm [4]. In Tanzania, 11% of births are premature
a n dp r e m a t u r i t yi st h es e c o n dl e a d i n gc a u s eo fn e o n a t a l
death [5]. In a study of hospitalized neonates in Tanzania,
the neonatal mortality rate for preterm infants was twice as
high as that for full-term infants, 26% versus 13% [6].
Expending extra resources on additional medical care
for pregnant women with risk factors for prematurity could
reduce the incidence of prematurity. Not only would this
haveimmediatebenefits,suchasreducingneonatalmortality,
b u ti tc o u l da l s or e d u c et h er i s ko fc h r o n i cd i s e a s ed u et o
preterm delivery throughout the life course [7, 8]. This could
substantially lower long-term health expenditures.
The prevalence of HIV infection among Tanzanian
women is estimated to be 6.6% [9]. Given the significant
proportion of pregnant women who are HIV-infected in
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some regions of the world, it is important to determine
not only the risk factors for prematurity among the general
population but also risk factors for prematurity among HIV-
infected women, because such factors could be distinct from
those in HIV uninfected women.
As the 2015 deadline of the Millennium Development
G o a l s( M D G s )d r a w sn e a r ,i ti sc l e a rt h a tM D G4 ,t h eg o a l
of reducing the under-five child mortality rate by two-thirds
between 1990 and 2015, cannot be reached unless efforts
are drastically increased [10]. While under-five mortality is
declining in many countries, neonatal mortality still lags
behind. Since preterm birth is responsible for 11% of under-
five child mortality worldwide, knowledge of risk factors for
prematurity may help the global community to reach MDG
4[ 11]. This paper aims to contribute to the evidence base
needed for a reduction in premature delivery by finding
determinants of preterm and very preterm birth through the
analysis of a cohort of 927 HIV-infected Tanzanian women.
We examined potential risk factors for preterm delivery,
many of which were previously found to be associated with
preterm delivery in healthy populations.
2. Methods
2.1. Study Population and Design. Study participants were
enrolled in a trial of vitamin supplements on pregnancy
outcomes and HIV disease progression. Participants were
HIV-infected pregnant women living in Dar es Salaam, Tan-
zania.Womenwererecruitedfromfourprenatalclinics.They
were enrolled in the study between April 1995 and July 1997.
Inclusioncriteriaincluded12to27weeksgestation,intention
to continue residing in Dar es Salaam for at least one year
following delivery, World Health Organization (WHO) HIV
diseasestages1–3,andinformedconsenttoberandomizedto
atreatmentregimen.Thestudyhaspreviouslybeendescribed
in further detail [12–15].
Of 1078 women enrolled in the trial, 949 had a live
b i r t hw i t hk n o w ng e s t a t i o n a la g ea td e l i v e r y .F o rt h ep r e m a -
turity analyses, we excluded 22 additional women because
of missing data on key potential risk factors for preterm
birth including age, maternal literacy, maternal malaria, HIV
disease stage, hypertension status, height, or at least two
measures of weight during pregnancy. None of the women
reportedsmokingduringpregnancy.Thisresultedinasample
of 927 pregnant women.
Consistent with the Tanzanian Ministry of Health’s stan-
dard of prenatal care at the time of the study, study partic-
ipants were provided with anemia and malaria prophylaxis
during pregnancy. During pregnancy, all study participants
received daily doses of 400mg of ferrous sulfate and 5mg
of folic acid for anemia prophylaxis and weekly doses of
500mg of chloroquine phosphate for malaria prophylaxis.
Study participants were treated for hypertension and syphilis
during pregnancy if found to have either disease. Study
participants did not receive antiretrovirals (ARVs), as they
were not available in Tanzania at the time of the study.
The trial was approved by the Research and Publications
Committee of Muhimbili University of Health and Allied
Sciences, the ethics committee of the Tanzania Ministry of
Health’s National AIDS Control Program, and the Institu-
tional Review Board of the Harvard School of Public Health.
2.2. Measurements. Premature was defined as birth at fewer
than37weeksofgestationandveryprematurewasdefinedas
fewer than 34 weeks of gestation. Gestational age was based
o nl a s tm e n s t r u a lp e r i o d( L M P ) ,w h i c hw a ss e l f - r e p o r t e d
by the participant at both screening and enrollment. Fundal
h e i g h tw a sm e a s u r e da st h ed i s t a n c e ,i nc e n t i m e t e r s ,f r o m
the top of the pubic bone to the top of the uterus by trained
doctors during the screening visit.
Anthropometric measurements, genital swabs, and
blood, urine, and stool samples were collected at enrollment.
These specimens were used to diagnose malaria, sexually
transmitted infections (STIs), and parasitic infections and
to measure micronutrient levels, hemoglobin concentration,
HIV viral load, and CD4 cell count. By design, vitamin A,
vitamin E, viral load, parasitic infections, and STIs were only
measured in a subsample of study participants.
The following STIs were tested for at enrollment: tri-
chomoniasis, gonorrhea, syphilis, and vaginal candidiasis.
Syphilis was diagnosed as active if syphilis antibodies from
sera were found to be present by both the Venereal Disease
Research Laboratory (VDRL; Murex Diagnostic, Dartford,
United Kingdom) and Treponema pallidum haemagglutina-
tion (TPHA; Fijurebio, Tokyo, Japan) tests. Gonorrhea was
diagnosed based on a culture of the genital swab to detect
NeisseriagonorrheaandTrichomonas vaginalis wasdiagnosed
based upon wet mounts that were prepared and examined
using microscopy. Vaginal candidiasis was diagnosed clini-
c a l l yb yp h y s i c i a ne x a m .
The following intestinal parasitic infections were tested
for at enrollment: Ascaris lumbricoides, Cryptosporidium
parvum, Entamoeba coli, Entamoeba histolytica, Enterobius,
Giardia lamblia,hookworm,isospora,microsporidia,Strong-
lyoides stercoralis, Taenia, and Trichuris trichiura.S t o o ls a m -
ples were examined macroscopically for the previously men-
tioned worms and microscopically using saline and iodine
wet mount and the formalin-ether concentration technique
for larvae, ova, and cysts.
Malaria was diagnosed by use of thick-smear blood films
stained with Giemsa. Vitamin A deficiency was defined
as plasma vitamin A <20𝜇g/dL. Low vitamin E levels
were defined as plasma vitamin E <9.7 𝜇mol/L. CD4 cell
countsweredichotomizedby<200cell/mm
3.W eca tegorized
hemoglobin levels according to three cutpoints: 7.0, 8.5,
and 11.0g/L. The WHO defines anemia in pregnancy as
a hemoglobin concentration below 11g/dL [16]. Prehyper-
tension was defined as systolic blood pressure (SBP) ≥120
or diastolic blood pressure (DBP) ≥80 and hypertension
was defined as SBP ≥140 or DBP ≥90 [17]. Selenium and
mid-upper arm circumference (MUAC) were categorized by
quartile. WHO HIV disease stage was dichotomized (stage <
2v e r s u ss t a g e≥ 2 )b e c a u s eo ft h el i m i t e dn u m b e ro fw o m e n
with HIV stage >2.
Trained research nurses interviewed study participants
at enrollment. Maternal age and relationship status wereObstetrics and Gynecology International 3
self-reported. Maternal age at conception was estimated by
subtracting gestational age at enrollment from maternal age
at enrollment. Having a partner was defined as self-report of
being married or cohabiting.
2.3. Statistical Analyses. Prematurity status, the outcome
variable, was determined based on self-reported LMP. In
order to validate the quality of LMP as a measure of gesta-
tional age we performed a supplemental analysis where we
calculatedtheSpearmancorrelationbetweengestationalages
b a s e do nL M Pa n df u n d a lh e i g h t .
Risk factors measured at enrollment that we examined
were mother’s age at conception, having no partner, being
illiterate, mid-upper arm circumference (MUAC), height,
vitamin A, vitamin E, selenium, hemoglobin, malaria, par-
asitic infections, STIs, HIV disease stage ≥ 2, CD4 cell
count, and viral load. Whether or not the pregnancy resulted
in twins and weight change during pregnancy were also
included as exposures. Although the Tanzania Vitamin and
HIVInfectionTrialfoundthatmultivitaminsreducedtherisk
of very preterm delivery [12], we did not adjust for assigned
vitamin regimen because vitamin regimen was randomized
and thus did not confound the relationships between the risk
factors we examined and preterm delivery.
Weight change during pregnancy was calculated for each
individual by using linear regression to regress weight on
week of gestation [18–20]. Weight change was then catego-
r i z e di n t ot h r e eg r o u p s :n og a i n( ≤0 grams per week), gain
below the 25th percentile, and gain at or above the 25th
percentile.
Missing indicators were created for each of the parasitic
infections, each of the STIs, viral load, CD4 count, vitamin
A deficiency, vitamin E, selenium, hemoglobin, and MUAC
[21].
Unadjusted and adjusted relative risk regression models
were run to calculate relative risks (RRs) and 95% confidence
intervals (CIs) [22]. Log-binomial regression was used for
all unadjusted regressions. Poisson was used for the adjusted
regressions because the adjusted log-binomial regressions
did not converge. Each regression was run twice, once with
preterm versus full term as the dependent variable and
again with very preterm versus full term as the dependent
variable.Deliveriesof≥34–<37weekswereexcludedfromthe
very preterm versus full term analysis. Explanatory variables
were included in the adjusted models if the 𝑃-value in the
unadjusted model was less than 0.2 [23]. Wald tests for trend
were calculated forcategorical variables by takingthe median
value of each category and setting missing values to the
overall median. Wald tests were calculated for dichotomous
and continuous variables.
WecalculatedaSpearmancorrelationcoefficientcompar-
ing gestational age as measured by LMP and fundal height
on 1077 women. The analysis included data on all trial
participants with a known LMP and fundal height at the
screening visit, excluding only one woman who was missing
data on LMP.
A 𝑃 value of ≤0.05 was considered to be statistically
significant. All statistical analyses were performed using SAS
software 9.3 (SAS Institute, Inc., http://www.sas.com, Cary,
North Carolina).
3. Results
The median gestational age at enrollment was 21 weeks (IQR
18–23). The median gestational age at delivery was 39 weeks
(IQR 37–41). Seventy-six percent of deliveries were full-
term, 24% were premature and 9% were very premature. The
characteristics of the cohort are shown in Table 1.
The results of unadjusted and adjusted relative risk
regressionsassessingtherelationshipsofmaternalfactorsand
the risk for preterm versus full-term deliveries are shown in
Table 2.A ft e ra d j u s t m e n t ,m a t e r n a la g el e s st h a n2 0y e a r s
(RR, 1.46; 95% CI, 1.10–1.95), maternal illiteracy (RR, 1.54;
95% CI, 1.10–2.61), low weight gain during pregnancy (𝑃
for trend = 0.006), malaria (RR, 1.42; 95% CI, 1.11–1.81),
Entamoeba coli infection (RR, 1.49; 95% CI, 1.04–2.15), and
HIV disease stage ≥ 2 (RR, 1.41; 95% CI, 1.12–1.79), and
prehypertension or hypertension (RR, 1.26; 95% CI, 1.00–
1.59) were significantly and independently associated with
increased risk of preterm delivery. After adjustment, vitamin
A deficiency, Entamoeba histolytica infection, and carrying
twins were all associated with an increased risk of preterm
delivery with borderline significance.
Theresultsofunadjustedandadjustedrelativeriskregres-
sions comparing maternal factors for very preterm versus
full-term deliveries are presented in Table 3.M a t e r n a la g e
less than 20 years (RR, 1.91; 95% CI, 1.21–3.03), small MUAC
(𝑃 for trend = 0.03), low weight gain during pregnancy (𝑃
for trend = 0.0005), malaria (RR, 1.81; 95% CI, 1.19–2.76),
Entamoeba coli infection (RR, 2.38; 95% CI, 1.38–4.09), and
Entamoebahistolyticainfection(RR,2.62;95%CI,1.09–6.28),
and HIV disease stage ≥ 2 (RR, 1.68; 95% CI, 1.11–2.53) were
significantly and independently associated with increased
risk of preterm delivery. Maternal illiteracy was associated
with increased risk of very preterm delivery with borderline
significance.
For the analysis, we dichotomized maternal age with
ac u t p o i n ta t2 0y e a r s .W ec h o s en o tt oi n c l u d ea na g e
group for older mothers because analyses showed that the
risk of prematurity in mothers aged 30 and older was not
significantly greater than the risk of prematurity in mothers
aged 20 to 30 (data not shown).
There may be concern that gestational age based on self-
r e p o r t e dL M Pi sp o t e n t i a l l yu n r e l i a b l e .H o w e v e r ,w ef o u n da
c o r r e l a t i o no f0 . 7 8( 9 5 %C I ,0 . 7 6 – 0 . 8 0 )b e t w e e ng e s t a t i o n a l
a g ea tsc r e e n i n gb a se do nL M Pa n dfu n d a lh e i gh t ,s u gg e s ti n g
that, for this population, self-reported LMP can be used as a
reasonable measure of gestational age.
4. Discussion
4.1. Main Findings. Our study found that HIV disease stage
≥ 2, no or low weight gain during pregnancy, Entamoeba
coli, malaria, and maternal age less than 20 years were
significantlyassociatedwithriskofpretermandverypreterm4 Obstetrics and Gynecology International
Table 1: Study population characteristics, 𝑁 = 927
a.
Characteristic 𝑁 (%) or median [IQR]
Preterm births (<37wks) 227 (24%)
Very preterm births (<34wks) 87 (9%)
Gestational age at enrollment (weeks) 21 [18, 23]
Gestational age at birth (weeks) 39 [37, 41]
Sociodemographic
Maternal age at conception (years) 25 [22, 29]
<20 96 (10%)
No partner 103 (11%)
Illiterate 70 (8%)
Nutrition and Anthropometric
Plasma vitamin A (𝜇g/dL) 23.4 [17.9, 30.2]
<20 246 (34%)
Plasma vitamin E (𝜇mol/L) 9.6 [8.0, 11.4]
<9.7 368 (51%)
Selenium (mg/mL) 0.12 [0.11, 0.14]
<0.11 218 (26.49%)
0.11-0.12 148 (17.98%)
0.12–0.14 250 (30.38%)
≥0.14 207 (25.15%)
Hemoglobin (g/dL) 9.5 [8.4, 10.5]
<7.0 59 (6%)
7.0–8.4 188 (21%)
8.5–10.9 508 (56%)
≥11.0 112 (12%)
Mid-upper arm circumference (cm) 25.0 [23.5, 27.5]
≤23.5 225 (26%)
23.6–25.0 203 (24%)
25.1–27.5 220 (26%)
>27.5 203 (24%)
Weight gain (g per week) 255 [116, 380]
≤01 1 2 ( 1 2 % )
1–119 126 (14%)
≥120 689 (74%)
Height (cm) 156 [152, 160]
<150 90 (10%)
Infections
Malaria 176 (19%)
Hookworm 92 (12%)
Entamoeba coli 69 (9%)
Ascaris lumbricoides 43 (6%)
Cryptosporidium parvum 34 (4%)
Entamoeba histolytica 15 (2%)
Strongyloides stercoralis 14 (2%)
Trichuris trichiura 9 (1%)
Giardia lamblia 4 (1%)
Enterobius 0 (0%)
Isospora 0 (0%)
Microsporidia 0 (0%)
Taenia 0 (0%)
Table 1: Continued.
Characteristic 𝑁 (%) or median [IQR]
Trichomoniasis 232 (25%)
Syphilis 44 (6%)
Vaginal candidiasis 41 (6%)
Gonorrhea 9 (1%)
HIV/AIDS
WHO HIV disease stage ≥ 2 189 (20%)
CD4 count (cells/mm
3)4 0 2 [275, 530]
<200 112 (13%)
Viral load (copies/mL) 47819 [11626, 146135]
≥50,000 193 (50%)
Other clinical variables
Twins 22 (2%)
Diastolic blood pressure (mmHg) 70 [60, 70]
Systolic blood pressure (mmHg) 110 [100, 110]
Prehypertension or hypertension
b 259 (28%)
AIQR: interquartile range.
aNot all numbers add up to 927 due to missing data.
bSystolic blood pressure > 120mmHg or diastolic blood pressure >
80mmHg.
delivery. Illiteracy and pre-hypertension/hypertension were
associated with preterm delivery; however, the relationship
ofilliteracywithverypretermwasonlyborderlinesignificant
and pre-hypertension/hypertension was not associated with
very preterm delivery. Entamoeba histolytica,a ni n t e s t i n a l
parasitic infection, and MUAC were associated with very
preterm delivery but not preterm delivery.
4.2. Strengths and Limitations. Although there have been
several studies on risk factors for premature delivery, this
s t u d yi su n i q u ei nt h a ti ti sb a s e du p o nal a r g es a m p l eo f
HIV-infected, ART-na¨ ıve pregnant women in sub-Saharan
A f r i c a .H o w e v e r ,t h e r ea r es o m ep o t e n t i a ll i m i t a t i o n st o
our study and analyses. Many of the potential risk factors
we examined were only measured at enrollment and not
throughout the pregnancy. Additional useful information
w o u l dh a v eb e e no b t a i n e di fl a bs a m p l e sh a db e e nt a k i n g
throughout participants’ pregnancies, since this would have
provided more complete data on parasitic infections, STIs,
HIV disease progression, and nutritional status throughout
pregnancy.
The potential lack of reliability of using LMP to estimate
gestational age is a limitation to our study, although this
approach is used frequently, both clinically and for research,
in sub-Saharan Africa given the expense and lack of access
to ultrasoundmachines. We expect that the definitionof pre-
maturity will be misclassified in a random way with respect
to various strata of a particular risk factor in our analyses.
Thus, we expect that our findings are biased towards the null
because nondifferential exposure of a binary outcome will
bias the results towards the null [24]. We found gestational
age based on fundal height and LMP to be highly correlated.
However, ultrasound, not fundal height measurements is the
gold standard for measuring gestational age. Fundal height
i st h o u g h tt ob ea c c u r a t et o1 – 3w e e k s .Af u t u r es t u d yObstetrics and Gynecology International 5
Table 2: Risk factors for preterm birth (<37 weeks versus ≥37 weeks), 𝑁 = 927.
Characteristic Unadjusted Adjusted
a
RR [95% CI] 𝑃 value RR [95% CI] 𝑃 value
Sociodemographic
Age < 20 at conception 1.58 [1.18, 2.11] 0.002 1.47 [1.10, 1.97] 0.01
No partner 1.17 [0.84, 1.63] 0.35
Illiterate 1.58 [1.14, 2.20] 0.006 1.53 [1.09, 2.15] 0.01
Nutrition
Plasma vitamin A < 20 (𝜇g/dL) 1.24 [1.19, 1.96] 0.0008 1.25 [0.97, 1.62] 0.08
Plasma vitamin E < 9.7 (𝜇mol/L) 0.88 [0.69, 1.13] 0.31
Selenium (mg/mL) 0.12 0.16
<0.11 1.37 [0.97, 1.96] 1.40 [0.98, 2.00]
0.11-0.12 1.15 [0.77, 1.73] 1.11 [0.74, 1.65]
0.12–0.14 1.39 [0.98, 1.95] 1.48 [1.05, 2.08]
≥0.14 Reference Reference
Hemoglobin (g/dL) 0.11 0.90
<7.0 1.29 [0.83, 2.01] 0.98 [0.64, 1.52]
7.0–8.4 1.05 [0.74, 1.49] 0.90 [0.63, 1.28]
8.5–10.9 0.82 [0.60, 1.11] 0.78 [0.58, 1.07]
≥11.0 Reference Reference
Mid-upper arm circumference (cm) 0.19 0.23
≤23.5 1.29 [0.92, 1.81] 1.32 [0.93, 1.87]
23.6–25.0 0.95 [0.66, 1.39] 0.91 [0.63, 1.33]
25.1–27.5 1.11 [0.78, 1.58] 1.07 [0.75, 1.53]
>27.5 Reference Reference
Weight gain (g per week) <0.0001 0.006
≤0 1.95 [1.51, 2.53] 1.60 [1.20, 2.14]
1–120 1.18 [0.85, 1.65] 1.12 [0.81, 1.57]
≥120 Reference Reference
Height < 150cm 0.95 [0.64, 1.40] 0.79
Infections
Malaria 1.53 [1.20, 1.96] 0.0006 1.41 [1.10, 1.81] 0.006
Hookworm 1.30 [0.92, 1.84] 0.13 1.19 [0.83, 1.70] 0.34
Entamoeba coli 1.49 [1.04, 2.14] 0.03 1.49 [1.04, 2.15] 0.03
Ascaris lumbricoides 1.21 [0.73, 1.99] 0.46
Cryptosporidium parvum 0.88 [0.45, 1.72] 0.70
Entamoeba histolytica 1.73 [0.92, 3.27] 0.09 1.79 [0.99, 3.26] 0.06
Strongyloides stercoralis 1.23 [0.53, 2.84] 0.63
Trichuris trichiura 1.44 [0.56, 3.65] 0.45
Trichomoniasis 1.18 [0.92, 1.52] 0.19 1.13 [0.88, 1.45] 0.35
Syphilis 1.28 [0.80, 2.05] 0.31
Vaginal candidiasis 1.10 [0.66, 1.85] 0.72
Gonorrhea 1.83 [0.88, 3.85] 0.11 1.68 [0.84, 3.35] 0.14
HIV/AIDS
WHO HIV disease stage ≥ 2 1.60 [1.26, 2.03] 0.0001 1.40 [1.11, 1.78] 0.005
CD4 count < 200 cells/mm
3 0.92 [0.64, 1.32] 0.65
Viral load ≥ 50,000 copies/mL 1.02 [0.74, 1.42] 0.89
Other clinical variables
Twins 1.50 [0.85, 2.64] 0.16 1.85 [0.94, 3.66] 0.07
Prehypertension or hypertension
b 1.25 [0.98, 1.58] 0.07 1.27 [1.01, 1.60] 0.04
ARR: risk ratio; CI: confidence interval.
aAdjusted for age < 20 years, literacy, plasma vitamin A < 20𝜇g/dL, selenium, mid-upper arm circumference, weight gain, malaria, hookworm, Entamoeba
coli, Entamoeba histolytica, trichomoniasis, gonorrhea, WHO HIV disease stage ≥ 2, twins, and prehypertension or hypertension.
bSystolic blood pressure >120mmHg or diastolic blood pressure >80mmHg.6 Obstetrics and Gynecology International
Table 3: Risk factors for very preterm birth (<34 weeks versus ≥37 weeks), 𝑁 = 787.
Characteristic Unadjusted Adjusted
a
RR [95% CI] 𝑃 value RR [95% CI] 𝑃 value
Sociodemographic
Age < 20 at conception 2.21 [1.37, 3.55] 0.001 1.94 [1.22, 3.06] 0.005
No partner 1.20 [0.66, 2.16] 0.55
Illiterate 1.93 [1.09, 3.41] 0.02 1.66 [0.91, 3.02] 0.10
Nutrition
Plasma vitamin A < 20 (𝜇g/dL) 1.89 [1.24, 2.87] 0.003 1.38 [0.89, 2.13] 0.15
Plasma vitamin E < 9.7 (𝜇mol/L) 0.86 [0.57, 1.32] 0.50
Selenium (mg/mL) 0.003 [<0.01, 58] 0.24
<0.11 1.64 [0.87, 3.09]
0.11-0.12 1.13 [0.53, 2.40]
0.12–0.14 1.82 [1.00, 3.32]
≥0.14 Reference
Hemoglobin (g/dL) 0.45
<7.0 0.72 [0.43, 1.23]
7.0–8.4 0.72 [0.43, 1.23]
8.5–10.9 1.12 [0.63, 2.01]
≥11.0 Reference
Mid-upper arm circumference (cm) 0.03 0.03
≤23.5 1.90 [0.99, 3.67] 2.07 [1.03, 4.16]
23.6–25.0 1.50 [0.75, 3.00] 1.50 [0.74, 3.06]
25.1–27.5 1.10 [0.52, 2.32] 1.03 [0.49, 2.20]
>27.5 Reference Reference
Weight gain (g per week) <0.0001 0.0005
≤0 3.21 [2.06, 5.00] 2.32 [1.36, 3.96]
1–120 1.78 [1.05, 3.03] 1.85 [1.05, 3.25]
≥120 Reference Reference
Height < 150cm 0.93 [0.47, 1.86] 0.84
Infections
Malaria 2.03 [1.34, 3.07] 0.0009 1.87 [1.20, 2.89] 0.005
Hookworm 1.18 [0.61, 2.27] 0.63
Entamoeba coli 2.34 [1.36, 4.02] 0.002 2.38 [1.38, 4.09] 0.002
Ascaris lumbricoides 1.34 [0.58, 3.13] 0.49
Cryptosporidium parvum 0.64 [0.17, 2.50] 0.53
Entamoeba histolytica 2.44 [0.89, 6.66] 0.08 2.62 [1.09, 6.28] 0.03
Strongyloides stercoralis 0.86 [0.13, 5.65] 0.88
Trichuris trichiura No data
Trichomoniasis 1.30 [0.84, 1.99] 0.24
Syphilis 1.34 [0.58, 3.13] 0.49
Vaginal candidiasis 0.82 [0.27, 2.45] 0.72
Gonorrhea 2.61 [0.80, 8.57] 0.11 2.72 [0.86, 8.58] 0.09
HIV/AIDS
WHO HIV disease stage ≥ 2 2.09 [1.39, 3.14] 0.0004 1.67 [1.11, 2.51] 0.01
CD4 count < 200 cells/mm
3 0.72 [0.36, 1.45] 0.36
Viral load ≥ 50,000 copies/mL 0.79 [0.46, 1.36] 0.40
Other clinical variables
Twins 2.06 [0.85, 5.00] 0.11 1.86 [0.68, 5.07] 0.22
Prehypertension or hypertension
b 1.16 [0.76, 1.79] 0.49 1.22 [0.81, 1.85] 0.33
ARR: risk ratio; CI: confidence interval.
aAdjusted for age <20years,literacy,plasmavitaminA<20𝜇g/dL,mid-upperarmcircumference,weightgain,malaria,Entamoebacoli,Entamoebahistolytica,
gonorrhea, WHO HIV disease stage ≥ 2, twins, and prehypertension or hypertension.
bSystolic blood pressure > 120mmHg or diastolic blood pressure > 80mmHg.Obstetrics and Gynecology International 7
comparing gestational age based on LMP versus ultrasound
in a developing country context, where recall of LMP may be
especially inaccurate, could provide further information on
the reliability of gestational age based on self-reported LMP.
Our study took place before zidovudine (AZT) and other
ARVs were in use in Tanzania, allowing us to identify risk
factors for prematurity among children born to ARV-naive
HIV-positive women. The use of highly active antiretroviral
therapy (HAART), but not AZT monotherapy, during preg-
nancyhasbeenshowntoincreasetheriskofpretermdelivery
[25]. In 2012, only 71% of HIV-infected pregnant women
in Tanzania were receiving ARVs for prevention of mother-
to-child transmission (PMTCT) [26]. This indicates that in
Tanzania the risk factors we have found for preterm delivery
in HIV-infected women are directly relevant for 29% of the
pregnancies in HIV-infected women. A review of PMTCT
coverage in 108 countries between 2007 and 2009 found that
only 35% of HIV-infected pregnant women received PMCTC
[27]. The WHO estimates that in 21 priority countries in sub-
Saharan Africa in 2012, only 64% of HIV-infected pregnant
women received any ARVs for PMCTC [28]. Among these
21 countries, PMCTC coverage ranged from 13% in the
DemocraticRepublicoftheCongoto>95%inbothBotswana
and Zambia [28].
Furthermore, the WHO guidelines recommend that low-
income countries choose from one of three options (A, B,
or B+) for PMTCT. The guidelines suggest that all patients
with a CD4 count of <350cells/mm
3 begin HAART and
that pregnant women with CD4 counts >350cells/mm
3 be
provided with either option A, B, or B+. Option A is the
provision of AZT monotherapy beginning at no sooner than
14 weeks gestation. Option B is the provision of HAART
beginning at no sooner than 14 weeks gestation. Option
B+ is the provision of HAART as soon as HIV infection is
d i a g n o s e d .W h i l es o m ec o u n t r i e sh a v ea d o p t e do p t i o nBo r
B+ for prevention of mother-to-child transmission of HIV,
several countries have opted to adopt Option A of the WHO
guidelines whereby women receive HAART only if they are
advanced in their disease. For example, Kenya has adopted
a combination of options A and B, in which health centers
adopt option A if they do not have the capacity to adopt
optionB[29].Inthesesettings,amajorityofpregnantwomen
areinearlystagesofdiseaseandarethusnotinitiatedontriple
ARVs, and for whom our findings are applied.
4.3. Interpretation. Preterm delivery and very preterm deliv-
erywereanalyzedasseparateoutcomesfortworeasons.First,
because very preterm delivery leads to more severe health
outcomes than preterm delivery, identification of differing
risk factors would make possible the targeting of available
resourcestowardverypretermdeliveryprevention.However,
we found that risk factors for very preterm and preterm
deliveries were similar. Our results suggest that the same
interventions can be used to reduce both preterm and very
preterm deliveries. Furthermore, analyzing preterm and very
preterm deliveries separately provided a sensitivity analysis.
The regression analysis of very preterm deliveries excluded
deliveries between 34 and 37 weeks, reducing misclassi-
fication bias that may be associated with gestational age
assessment.
Because very preterm deliveries are a subset of preterm
deliveries, they have a smaller sample size, resulting in larger
standard errors and 𝑃 values,andwider confidenceintervals.
Many of the point estimates are larger in the very preterm
regression. This may be because there is less misclassification
bias due to incorrectly estimated gestational age. Deliveries
with a reported gestational age of less than 34 weeks were
more likely to be correctly classified as preterm than those
with a reported gestational age of less than 37 weeks.
The rate of prematurity that we observed, 24%, is higher
than that found in other HIV-infected populations. A study
of1626HIV-positiveNigerianwomenfrom2004–2010found
a preterm delivery rate of 11.1% [30]. This may partially be
d u et oi m p r o v e m e n t si nn u t r i t i o na n dm a t e r n a lh e a l t hf r o m
1995–1997 to 2004–2010. A study in the United States in the
early 1990’s found that 19% of infants born to HIV-infected
mothers were premature [31]. This difference is likely due, in
part, to better healthcare in the US.
We found lack of weight gain during pregnancy to be
associated with preterm and very preterm delivery. Weight
g a i ni sam a r k e ro fm a t e r n a ln u t r i t i o n a ls t a t u s ,a n dt h u sn o
or low weight gain during pregnancy could be a marker of
inadequatenutritionduringpregnancy.However,thisfinding
may be due to reverse causality, as it is unknown whether
lack of weight gain caused the premature delivery or the
prematuredeliveryledtolesstimeforgestationalweightgain.
We found that HIV disease stage ≥ 2 at enrollment
increased the risk of prematurity. However, we did not find
any further association between prematurity and either CD4
cell count or viral load. A study in South Africa found no
effect of HIV-infection in ART-na¨ ıve women on prematurity
[32]. However, a previous study in China did report an effect
o fC D 4c o u n ta n dv i r a ll o a do np r e m a t u r i t y[ 33].
We found younger maternal age, but not older maternal
age, to be a risk factor for preterm birth. Women younger
than20yearsweremorelikelytodeliverpretermcomparedto
women 20 years and older. However, women 30 years of age
and older were not found to be at a higher risk of premature
d e l i v e r yc o m p a r e dt ow o m e na g e d2 0 – 3 0 .Th er e s u l tt h a t
youngmothersareatanincreasedriskforprematuredelivery
has also been found in studies in other sub-Saharan African
countries such as Cameroon [34], but not Zimbabwe [35].
The result that older maternal age is not associated with
premature delivery was also found in a Turkish study that
found adolescent pregnancy to be a weak risk factor for
prematurity but did not find maternal age of 39 and older to
increase the risk of prematurity [36]. However, a study in the
US found women aged 30–34 and aged 35 and older to be at
an increased risk for premature delivery compared to women
aged 25–29 [37].
5. Conclusion
A st h ep r e v e n t a b l ea n dt r e a t a b l em a j o rk i l l e r so fc h i l d r e n
suchasmalaria,diarrhealdisease,andrespiratorydiseaseare8 Obstetrics and Gynecology International
increasingly managed, with the presumption that mortality
from these causes will decrease, the proportion of child
mortality due to premature birth will increase. In order to
further reduce needless child deaths, it will be important to
reduce the modifiable determinants of preterm birth so as to
increase the percentage of children that are born full-term.
Interventions to promote nutritional status and to slow HIV
disease progression are likely to be critical for reducing the
risk of prematurity.
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